Alnylam’s ALN-TTRSC04: A Promising Phase 1 Study Update

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.

Alnylam Pharmaceuticals is conducting a Phase 1 clinical study titled A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneously Administered ALN-TTRSC04 in Healthy Subjects. The study aims to assess the safety and tolerability of ALN-TTRSC04, a drug administered via subcutaneous injection, in healthy individuals. This research is significant as it explores the pharmacokinetics and pharmacodynamics of the drug, potentially paving the way for new treatments.

The intervention being tested is ALN-TTRSC04, an experimental drug designed to be administered through a single subcutaneous dose. The study also includes a placebo group for comparison.

The study follows an interventional design with a randomized, parallel assignment. It employs triple masking, meaning that the participant, care provider, and investigator are unaware of the group assignments. The primary purpose of the study is treatment-focused, aiming to gather initial data on the drug’s effects.

The study began on January 16, 2023, and is currently active but not recruiting participants. The last update was submitted on July 23, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.

This study update could influence Alnylam Pharmaceuticals’ stock performance by potentially boosting investor confidence if the results are favorable. As the study progresses, it may impact the competitive landscape in the pharmaceutical industry, particularly in the field of RNA interference therapeutics.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.